No Effect of Anti-TNF-α Treatment on Serum IL-17 in Patients with Rheumatoid Arthritis

Overview

Journal Cent Eur J Immunol

Publisher Termedia

Specialty Allergy & Immunology

Date 2018 Dec 28

PMID 30588171

Citations 3

Authors

Dorota Sikorska

Rafal Rutkowski

Joanna Luczak

Wlodzimierz Samborski

Janusz Witowski

Affiliations

Soon will be listed here.

Abstract

Introduction: Interleukin 17 (IL-17) and CC-chemokine ligand 20 (CCL20) are increasingly implicated in the pathogenesis of rheumatoid arthritis (RA). A correlation has been reported to exist between serum levels of IL-17 and CCL20 and the disease activity. However, such an effect has not been universally demonstrated. The aim of the present study was to investigate if serum levels of IL-17 and/or CCL20 reflect the disease activity and response to anti-TNF- therapy in patients with RA.

Material And Methods: Twenty-two RA patients qualified to receive anti-TNF- treatment were prospectively assessed before and after 12 weeks of therapy. Serum concentrations of IL-17 and CCL20 were measured with high-sensitivity immunoassays. Disease activity was assessed by the 28-joint disease activity score (DAS28).

Results: Twelve weeks of therapy resulted in a satisfactory therapeutic response in the majority (91%) of patients (reflected both by clinical and standard biochemical criteria). However, serum concentrations of IL-17 and CCL20 did not change significantly over the course of therapy Moreover, they did not correlate with the disease activity, patient characteristics, and their response to therapy.

Conclusions: Serum levels of IL-17 and CCL20 do not reflect changes in the clinical and biochemical status that occur in patients undergoing anti-TNF- treatment for RA. The lack of such an association indicates that IL-17 signalling is not affected by anti-TNF- therapy and is thus not critically involved in the disease pathogenesis.

Citing Articles

Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis.

Hammoura I, Fiechter R, Bryant S, Westmoreland S, Kingsbury G, Waegell W Int J Mol Sci. 2022; 23(2).

PMID: 35055042 PMC: 8776047. DOI: 10.3390/ijms23020859.

Chronic inflammation and the growth hormone/insulin-like growth factor-1 axis.

Witkowska-Sedek E, Pyrzak B Cent Eur J Immunol. 2021; 45(4):469-475.

PMID: 33613096 PMC: 7882400. DOI: 10.5114/ceji.2020.103422.

IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.

Zhang B, Jiang W Inflammopharmacology. 2019; 27(6):1123-1130.

PMID: 31463666 DOI: 10.1007/s10787-019-00624-2.

References

Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Ishida H . Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol. 1999; 19(5):305-13. DOI: 10.1023/a:1020543625282. View

Barrera P, Joosten L, den Broeder A, van de Putte L, van Riel P, van den Berg W . Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis. 2001; 60(7):660-9. PMC: 1753753. DOI: 10.1136/ard.60.7.660. View

Koenders M, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen M, Di Padova F . Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005; 167(1):141-9. PMC: 1603454. DOI: 10.1016/S0002-9440(10)62961-6. View

Raza K, Falciani F, Curnow S, Ross E, Lee C, Akbar A . Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005; 7(4):R784-95. PMC: 1175027. DOI: 10.1186/ar1733. View

Acosta-Rodriguez E, Napolitani G, Lanzavecchia A, Sallusto F . Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007; 8(9):942-9. DOI: 10.1038/ni1496. View

Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi J, Kaibara N . Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 67(9):1299-304. DOI: 10.1136/ard.2007.080341. View

Gaffen S . Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009; 9(8):556-67. PMC: 2821718. DOI: 10.1038/nri2586. View

Kageyama Y, Kobayashi H, Kato N . Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol. 2009; 19(6):657-62. DOI: 10.1007/s10165-009-0217-6. View

Kawashiri S, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M . Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol. 2009; 36(11):2397-402. DOI: 10.3899/jrheum.090132. View

10.

Yue C, You X, Zhao L, Wang H, Tang F, Zhang F . The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int. 2009; 30(12):1553-7. DOI: 10.1007/s00296-009-1179-x. View

11.

Shahrara S, Pickens S, Mandelin 2nd A, Karpus W, Huang Q, Kolls J . IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol. 2010; 184(8):4479-87. PMC: 2858914. DOI: 10.4049/jimmunol.0901942. View

12.

Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A . A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet. 2010; 42(6):515-9. DOI: 10.1038/ng.583. View

13.

Rasmussen T, Andersen T, Hvid M, Hetland M, Horslev-Petersen K, Stengaard-Pedersen K . Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol. 2010; 37(10):2014-20. DOI: 10.3899/jrheum.100259. View

14.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9):1580-8. DOI: 10.1136/ard.2010.138461. View

15.

Aerts N, De Knop K, Leysen J, Ebo D, Bridts C, Weyler J . Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford). 2010; 49(12):2264-72. DOI: 10.1093/rheumatology/keq224. View

16.

Mewar D, Wilson A . Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol. 2010; 162(4):785-91. PMC: 3042190. DOI: 10.1111/j.1476-5381.2010.01099.x. View

17.

Chen D, Chen Y, Chen H, Hsieh C, Lin C, Lan J . Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2011; 13(4):R126. PMC: 3239366. DOI: 10.1186/ar3431. View

18.

Metawi S, Abbas D, Kamal M, Ibrahim M . Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol. 2011; 30(9):1201-7. DOI: 10.1007/s10067-011-1737-y. View

19.

Sadik C, Kim N, Alekseeva E, Luster A . IL-17RA signaling amplifies antibody-induced arthritis. PLoS One. 2011; 6(10):e26342. PMC: 3197623. DOI: 10.1371/journal.pone.0026342. View

20.

Rosu A, Margaritescu C, Stepan A, Musetescu A, Ene M . IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients. Rom J Morphol Embryol. 2012; 53(1):73-80. View